

The Role of Epigenetics in Obesity-Driven Hyperlipidemia: Understanding Gene-Environment Interactions

Wambui Kibibi J.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity-driven hyperlipidemia, characterized by elevated levels of lipids in the blood, represents a significant risk factor for cardiovascular diseases. While genetic predisposition plays a role, epigenetic modifications have emerged as key mediators of the complex interactions between genes and environmental factors, including diet, physical activity, and lifestyle. Epigenetic mechanisms, such as DNA methylation, histone modifications, and non-coding RNAs, modulate gene expression without altering the underlying DNA sequence, influencing lipid metabolism and fat accumulation. This review explores the role of epigenetics in obesity-driven hyperlipidemia, focusing on the mechanisms by which environmental factors shape gene expression and contribute to metabolic dysregulation. We highlight recent advances in understanding how epigenetic alterations can predispose individuals to lipid disorders and examine potential therapeutic interventions that target these modifications to mitigate hyperlipidemia in obese individuals. Additionally, we discuss the importance of personalized medicine approaches in the prevention and management of obesity-related lipid disorders, considering individual epigenetic profiles.

Keywords: Obesity-driven hyperlipidemia; Epigenetic modifications; Lipid metabolism; DNA methylation; Personalized medicine

INTRODUCTION

Obesity is a global health challenge, contributing to a range of metabolic disorders, including hyperlipidemia, which is characterized by abnormally high levels of lipids such as cholesterol and triglycerides in the blood.[1, 2] The pathogenesis of hyperlipidemia in the context of obesity is multifactorial, involving both genetic and environmental factors[3-5]. While genetic predispositions to obesity and hyperlipidemia are well-established, emerging research highlights the crucial role of epigenetic mechanisms in mediating gene-environment interactions that drive lipid dysregulation are still been investigated.

Epigenetics refers to heritable changes in gene expression that occur without alterations in the DNA sequence[6, 7]. These modifications, including DNA methylation, histone modification, and regulation by non-coding RNAs, can be influenced by external factors such as diet, exercise, and environmental exposures. In obesity, these epigenetic changes may promote alterations

in lipid metabolism, leading to hyperlipidemia and associated cardiovascular risks[8, 9]. Understanding the epigenetic landscape in obesity-driven hyperlipidemia is essential for developing targeted therapeutic interventions.

Epigenetic Mechanisms in Obesity-Driven Hyperlipidemia

DNA Methylation: DNA methylation, the addition of a methyl group to cytosine residues in CpG dinucleotides, is a key epigenetic mechanism involved in gene silencing[10, 11]. In the context of obesity-driven hyperlipidemia, aberrant DNA methylation patterns have been observed in genes regulating lipid metabolism, including those involved in cholesterol synthesis, fatty acid oxidation, and adipogenesis. For instance, methylation of the peroxisome proliferator-activated receptor gamma (PPAR γ) gene, which plays a central role in adipocyte differentiation and lipid metabolism, has been associated with altered fat distribution and lipid profile in obese

individuals. Additionally, hypermethylation of the lipoprotein lipase (LPL) gene, a critical enzyme in triglyceride metabolism, has been linked to elevated plasma triglyceride levels in obesity [12, 13]. Environmental factors, particularly diet, can induce changes in DNA methylation. Diets high in saturated fats and sugar have been shown to alter methylation patterns of lipid-regulating genes, contributing to dyslipidemia in obese individuals. Conversely, dietary interventions, such as caloric restriction and the inclusion of methyl-donor nutrients like folate, may reverse these epigenetic modifications and improve lipid profiles.

Histone Modifications: Histones are proteins around which DNA is wrapped, and their post-translational modifications can influence chromatin structure and gene expression. Histone acetylation, methylation, phosphorylation, and ubiquitination have all been implicated in the regulation of genes involved in lipid metabolism. In obesity-driven hyperlipidemia, alterations in histone modifications have been found to promote lipogenesis and impair lipid breakdown [14]. For example, increased histone acetylation at the promoters of genes involved in cholesterol biosynthesis, such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), can lead to increased cholesterol production [14, 15]. Conversely, histone deacetylation may repress the expression of genes involved in fatty acid oxidation, contributing to the accumulation of lipids in tissues.

The dynamic nature of histone modifications makes them attractive targets for therapeutic intervention. Histone deacetylase inhibitors (HDACi), for example, have shown promise in modulating lipid metabolism by altering the expression of key lipid-regulating genes, offering a potential treatment for obesity-driven hyperlipidemia.

Non-Coding RNAs: Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play critical roles in post-transcriptional regulation of gene expression. In the context of obesity-driven hyperlipidemia, dysregulation of specific miRNAs has been implicated in the control of lipid metabolism and fat storage [16, 17].

Several miRNAs, such as miR-33 and miR-122, have been shown to regulate cholesterol homeostasis by targeting genes involved in lipid transport and synthesis [18]. Dysregulation of

these miRNAs in obesity may lead to increased circulating lipid levels and contribute to hyperlipidemia. Similarly, lncRNAs have been found to influence lipid metabolism by interacting with chromatin-modifying complexes or by acting as molecular sponges for miRNAs, further complicating the regulatory network [19]. Therapeutic strategies targeting ncRNAs, including miRNA mimics or inhibitors, hold potential for correcting dysregulated lipid metabolism in obesity. However, challenges remain in the delivery and specificity of these treatments.

Gene-Environment Interactions in Obesity-Driven Hyperlipidemia: The interplay between genetic predisposition and environmental factors, such as diet, physical activity, and exposure to toxins, is central to the development of obesity-driven hyperlipidemia. Epigenetic modifications serve as a molecular interface between these factors, mediating changes in gene expression that influence lipid metabolism.

Dietary Influences: Diet is a major modulator of epigenetic marks. High-fat and high-sugar diets can induce epigenetic changes that promote lipid accumulation, while dietary interventions, such as the Mediterranean diet, rich in fruits, vegetables, and healthy fats, have been shown to reverse some of these modifications, improving lipid profiles [20, 21].

Physical Activity: Exercise has been shown to influence epigenetic regulation of lipid metabolism genes, promoting favorable changes in lipid profiles. Regular physical activity can reduce DNA methylation in lipid-regulating genes, enhancing fatty acid oxidation and lowering cholesterol levels [22].

Environmental Exposures: Exposure to environmental toxins, such as endocrine-disrupting chemicals (EDCs), can induce epigenetic changes that affect lipid metabolism. These toxins may alter DNA methylation and histone modifications, leading to dysregulation of lipid homeostasis and the development of hyperlipidemia in obese individuals [23].

Therapeutic Implications

Understanding the epigenetic mechanisms underlying obesity-driven hyperlipidemia opens new avenues for therapeutic interventions. Targeting epigenetic modifications through dietary interventions, physical activity, and pharmacological agents may provide novel

strategies for managing hyperlipidemia in obese individuals.

Dietary Interventions: Nutrients that serve as methyl donors, such as folate, B vitamins, and choline, can modulate DNA methylation and improve lipid profiles. Dietary strategies aimed at restoring normal epigenetic regulation may reduce the risk of hyperlipidemia in obese individuals.

Pharmacological Interventions: Epigenetic drugs, including HDAC inhibitors and DNA methyltransferase inhibitors, are being explored as

Epigenetic modifications play a crucial role in mediating the gene-environment interactions that contribute to obesity-driven hyperlipidemia. Understanding these mechanisms provides valuable insights into the pathogenesis of lipid disorders and offers new opportunities for

potential treatments for metabolic disorders. These drugs may reverse aberrant epigenetic modifications and restore normal lipid metabolism in obesity-driven hyperlipidemia.

Personalized Medicine: Given the inter-individual variability in epigenetic modifications, personalized medicine approaches that consider an individual's epigenetic profile may be necessary for optimizing treatment strategies for obesity-related hyperlipidemia.

CONCLUSION

therapeutic intervention. As research in this field continues to evolve, personalized approaches that target specific epigenetic modifications may become central to the management and prevention of obesity-related hyperlipidemia.

REFERENCES

1. Calcaterra, V., Verduci, E., Milanta, C., Agostinelli, M., Bona, F., Croce, S., Valsecchi, C., Avanzini, M.A., Zuccotti, G.: The Benefits of the Mediterranean Diet on Inflamm-Aging in Childhood Obesity. *Nutrients*. 16, 1286 (2024). <https://doi.org/10.3390/nu16091286>
2. Camilleri, M., Acosta, A.: Combination Therapies for Obesity. *Metab Syndr Relat Disord*. 16, 390–394 (2018). <https://doi.org/10.1089/met.2018.0075>
3. Uti, D.E., Ibiyam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadam, S.K., Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. *Pharmaceutical Fronts*. 05, e141–e152 (2023). <https://doi.org/10.1055/s-0043-1772607>
4. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African Walnuts (*Tetracarpidium conophorum*) Modulate Hepatic Lipid Accumulation in Obesity via Reciprocal Actions on HMG-CoA Reductase and Paraoxonase. *Endocrine, Metabolic & Immune Disorders - Drug Targets(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)*. 20, 365–379 (2020). <https://doi.org/10.2174/1871530319666190724114729>
5. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in monosodium glutamate-obese Wistar rats. *Biomedicine & Pharmacotherapy*. 124, 109879(2020). <https://doi.org/10.1016/j.biopha.2020.109879>
6. Al Aboud, N.M., Tupper, C., Jialal, I.: Genetics, Epigenetic Mechanism. In: *StatPearls*. StatPearls Publishing, Treasure Island (FL) (2024)
7. Mohana Devi, S., Mahalaxmi, I., Kaavya, J., Chinnkulandhai, V., Balachandar, V.: Does epigenetics have a role in age related macular degeneration and diabetic retinopathy? *Genes & Diseases*. 8, 279–286 (2021). <https://doi.org/10.1016/j.gendis.2020.01.003>
8. Mahmoud, A.M.: An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. *Int J Mol Sci*. 23, 1341 (2022). <https://doi.org/10.3390/ijms23031341>
9. Smith, E.N.L., Chandanathil, M., Millis, R.M.: Epigenetic Mechanisms in Obesity: Broadening Our Understanding of the

- Disease. *Cureus*. 15, e47875. <https://doi.org/10.7759/cureus.47875>
10. Kiselev, I.S., Kulakova, O.G., Boyko, A.N., Favorova, O.O.: DNA Methylation As an Epigenetic Mechanism in the Development of Multiple Sclerosis. *Acta Naturae*. 13, 45 (2021). <https://doi.org/10.32607/actanaturae.11043>
 11. Breiling, A., Lyko, F.: Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. *Epigenetics & Chromatin*. 8, 24 (2015). <https://doi.org/10.1186/s13072-015-0016-6>
 12. Samblas, M., Milagro, F.I., Martínez, A.: DNA methylation markers in obesity, metabolic syndrome, and weight loss. *Epigenetics*. 14, 421–444 (2019). <https://doi.org/10.1080/15592294.2019.1595297>
 13. Nettore, I.C., Franchini, F., Palatucci, G., Macchia, P.E., Ungaro, P.: Epigenetic Mechanisms of Endocrine-Disrupting Chemicals in Obesity. *Biomedicines*. 9, 1716 (2021). <https://doi.org/10.3390/biomedicines9111716>
 14. Molina-Serrano, D., Kyriakou, D., Kirmizis, A.: Histone Modifications as an Intersection Between Diet and Longevity. *Front Genet*. 10, 192(2019). <https://doi.org/10.3389/fgene.2019.00192>
 15. Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., Zhang, H.: Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets. *MedComm* (2020). 4, e292(2023). <https://doi.org/10.1002/mco2.292>
 16. Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M.B., Valeri, N., Hahne, J.C.: MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. *Target Oncol*. 15, 261–278 (2020). <https://doi.org/10.1007/s11523-020-00717-x>
 17. Formichi, C., Nigi, L., Grieco, G.E., Maccora, C., Fignani, D., Brusco, N., Licata, G., Sebastiani, G., Dotta, F.: Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. *IJMS*. 22, 7716 (2021). <https://doi.org/10.3390/ijms22147716>
 18. Yang, Z., Cappello, T., Wang, L.: Emerging role of microRNAs in lipid metabolism. *Acta Pharmaceutica Sinica B*. 5, 145–150 (2015). <https://doi.org/10.1016/j.apsb.2015.01.002>
 19. Aryal, B., Singh, A.K., Rotllan, N., Price, N., Fernández-Hernando, C.: microRNAs and lipid metabolism. *Curr Opin Lipidol*. 28, 273–280(2017). <https://doi.org/10.1097/MOL.0000000000000420>
 20. Li, D., Li, Y., Yang, S., Lu, J., Jin, X., Wu, M.: Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. *Biomedicine & Pharmacotherapy*. 153, 113290 (2022). <https://doi.org/10.1016/j.biopha.2022.113290>
 21. Tiffon, C.: The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease. *Int J Mol Sci*. 19, 3425 (2018). <https://doi.org/10.3390/ijms19113425>
 22. Plaza-Diaz, J., Izquierdo, D., Torres-Martos, Á., Baig, A.T., Aguilera, C.M., Ruiz-Ojeda, F.J.: Impact of Physical Activity and Exercise on the Epigenome in Skeletal Muscle and Effects on Systemic Metabolism. *Biomedicines*. 10, 126 (2022). <https://doi.org/10.3390/biomedicines10010126>
 23. Zhang, Y., Wang, B., Sun, W., Wang, G., Liu, Z., Zhang, X., Ding, J., Han, Y., Zhang, H.: Paternal exposures to endocrine-disrupting chemicals induce intergenerational epigenetic influences on offspring: A review. *Environment International*. 187, 108689 (2024). <https://doi.org/10.1016/j.envint.2024.108689>

CITE AS: Wambui Kibibi J. (2024). The Role of Epigenetics in Obesity-Driven Hyperlipidemia: Understanding Gene-Environment Interactions. IAA Journal of Scientific Research 11(3):27-31. <https://doi.org/10.59298/IAAJSR/2024/113.2731>